Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
IDYA Quote, Financials, Valuation and Earnings
Last price:
$33.03
Seasonality move
:
0.99%
Day range:
$31.19 - $33.59
52-week range:
$13.45 - $39.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.41x
P/B ratio:
2.84x
Volume:
858K
Avg. volume:
840.8K
1-year change:
60.62%
Market cap:
$2.9B
Revenue:
$218.7M
EPS (TTM):
-$1.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$5.9M | -$0.95 | -15.05% | -19.67% | $50.06 |
|
AMGN
Amgen, Inc.
|
$9.5B | $4.73 | 6.72% | 50.75% | $350.04 |
|
BLTE
Belite Bio, Inc.
|
-- | -$0.54 | -- | -27.64% | $186.50 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.37% | 40.06% | $28.43 |
|
RZLT
Rezolute, Inc.
|
-- | -$0.18 | -- | -37.59% | $4.75 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$391M | -$0.77 | -36.5% | -91.57% | $21.55 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$33.04 | $50.06 | $2.9B | -- | $0.00 | 0% | 13.41x |
|
AMGN
Amgen, Inc.
|
$385.70 | $350.04 | $207.9B | 27.10x | $2.52 | 2.51% | 5.69x |
|
BLTE
Belite Bio, Inc.
|
$177.58 | $186.50 | $6.7B | -- | $0.00 | 0% | -- |
|
PFE
Pfizer Inc.
|
$27.26 | $28.43 | $155B | 20.12x | $0.43 | 6.31% | 2.48x |
|
RZLT
Rezolute, Inc.
|
$3.14 | $4.75 | $300.5M | -- | $0.00 | 0% | -- |
|
SRPT
Sarepta Therapeutics, Inc.
|
$16.32 | $21.55 | $1.7B | 20.50x | $0.00 | 0% | 0.76x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
2.66% | 1.481 | 0.92% | 10.87x |
|
AMGN
Amgen, Inc.
|
86.49% | -0.404 | 32.2% | 0.74x |
|
BLTE
Belite Bio, Inc.
|
0.19% | -0.933 | 0.02% | 34.17x |
|
PFE
Pfizer Inc.
|
43.81% | 0.308 | 49.24% | 0.70x |
|
RZLT
Rezolute, Inc.
|
0.99% | 4.519 | 0.57% | 13.95x |
|
SRPT
Sarepta Therapeutics, Inc.
|
47.41% | -0.225 | 45.6% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$9.7M | -$94.6M | -10.76% | -11.02% | -869.53% | -$90.8M |
|
AMGN
Amgen, Inc.
|
$8.1B | $3.9B | 11.96% | 102.03% | 39.83% | $961M |
|
BLTE
Belite Bio, Inc.
|
-$347K | -$23M | -37.09% | -37.13% | -- | -- |
|
PFE
Pfizer Inc.
|
$11B | $3.8B | 5.07% | 8.69% | 21.58% | $4.5B |
|
RZLT
Rezolute, Inc.
|
-$7K | -$24.2M | -67.11% | -67.99% | -- | -$20.3M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$34.1M | -$410.1M | -32.9% | -64.94% | -92.58% | -$55.6M |
IDEAYA Biosciences, Inc. vs. Competitors
-
Which has Higher Returns IDYA or AMGN?
Amgen, Inc. has a net margin of -765.66% compared to IDEAYA Biosciences, Inc.'s net margin of 13.47%. IDEAYA Biosciences, Inc.'s return on equity of -11.02% beat Amgen, Inc.'s return on equity of 102.03%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.88.99% -$0.94 $1.1B AMGNAmgen, Inc.81.91% $2.45 $64.1B -
What do Analysts Say About IDYA or AMGN?
IDEAYA Biosciences, Inc. has a consensus price target of $50.06, signalling upside risk potential of 51.52%. On the other hand Amgen, Inc. has an analysts' consensus of $350.04 which suggests that it could fall by -9.25%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Amgen, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 AMGNAmgen, Inc.9 17 2 -
Is IDYA or AMGN More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.092, which suggesting that the stock is 90.817% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.886%.
-
Which is a Better Dividend Stock IDYA or AMGN?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.51% to investors and pays a quarterly dividend of $2.52 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 66.92% of its earnings as a dividend. Amgen, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IDYA or AMGN?
IDEAYA Biosciences, Inc. quarterly revenues are $10.9M, which are smaller than Amgen, Inc. quarterly revenues of $9.9B. IDEAYA Biosciences, Inc.'s net income of -$83.3M is lower than Amgen, Inc.'s net income of $1.3B. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 27.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.41x versus 5.69x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.13.41x -- $10.9M -$83.3M AMGNAmgen, Inc.5.69x 27.10x $9.9B $1.3B
-
Which has Higher Returns IDYA or BLTE?
Belite Bio, Inc. has a net margin of -765.66% compared to IDEAYA Biosciences, Inc.'s net margin of --. IDEAYA Biosciences, Inc.'s return on equity of -11.02% beat Belite Bio, Inc.'s return on equity of -37.13%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.88.99% -$0.94 $1.1B BLTEBelite Bio, Inc.-- -$0.65 $274.6M -
What do Analysts Say About IDYA or BLTE?
IDEAYA Biosciences, Inc. has a consensus price target of $50.06, signalling upside risk potential of 51.52%. On the other hand Belite Bio, Inc. has an analysts' consensus of $186.50 which suggests that it could grow by 10.23%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Belite Bio, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Belite Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 BLTEBelite Bio, Inc.6 0 0 -
Is IDYA or BLTE More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.092, which suggesting that the stock is 90.817% less volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IDYA or BLTE?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or BLTE?
IDEAYA Biosciences, Inc. quarterly revenues are $10.9M, which are larger than Belite Bio, Inc. quarterly revenues of --. IDEAYA Biosciences, Inc.'s net income of -$83.3M is lower than Belite Bio, Inc.'s net income of -$21.7M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.41x versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.13.41x -- $10.9M -$83.3M BLTEBelite Bio, Inc.-- -- -- -$21.7M
-
Which has Higher Returns IDYA or PFE?
Pfizer Inc. has a net margin of -765.66% compared to IDEAYA Biosciences, Inc.'s net margin of -9.34%. IDEAYA Biosciences, Inc.'s return on equity of -11.02% beat Pfizer Inc.'s return on equity of 8.69%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.88.99% -$0.94 $1.1B PFEPfizer Inc.62.74% -$0.29 $154.2B -
What do Analysts Say About IDYA or PFE?
IDEAYA Biosciences, Inc. has a consensus price target of $50.06, signalling upside risk potential of 51.52%. On the other hand Pfizer Inc. has an analysts' consensus of $28.43 which suggests that it could grow by 4.28%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 PFEPfizer Inc.8 15 1 -
Is IDYA or PFE More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.092, which suggesting that the stock is 90.817% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.474, suggesting its less volatile than the S&P 500 by 52.65%.
-
Which is a Better Dividend Stock IDYA or PFE?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.31% to investors and pays a quarterly dividend of $0.43 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or PFE?
IDEAYA Biosciences, Inc. quarterly revenues are $10.9M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. IDEAYA Biosciences, Inc.'s net income of -$83.3M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.41x versus 2.48x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.13.41x -- $10.9M -$83.3M PFEPfizer Inc.2.48x 20.12x $17.6B -$1.6B
-
Which has Higher Returns IDYA or RZLT?
Rezolute, Inc. has a net margin of -765.66% compared to IDEAYA Biosciences, Inc.'s net margin of --. IDEAYA Biosciences, Inc.'s return on equity of -11.02% beat Rezolute, Inc.'s return on equity of -67.99%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.88.99% -$0.94 $1.1B RZLTRezolute, Inc.-- -$0.22 $129.3M -
What do Analysts Say About IDYA or RZLT?
IDEAYA Biosciences, Inc. has a consensus price target of $50.06, signalling upside risk potential of 51.52%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.75 which suggests that it could grow by 51.27%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Rezolute, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Rezolute, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 RZLTRezolute, Inc.5 4 0 -
Is IDYA or RZLT More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.092, which suggesting that the stock is 90.817% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.512, suggesting its less volatile than the S&P 500 by 48.763%.
-
Which is a Better Dividend Stock IDYA or RZLT?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or RZLT?
IDEAYA Biosciences, Inc. quarterly revenues are $10.9M, which are larger than Rezolute, Inc. quarterly revenues of --. IDEAYA Biosciences, Inc.'s net income of -$83.3M is lower than Rezolute, Inc.'s net income of -$22.8M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.41x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.13.41x -- $10.9M -$83.3M RZLTRezolute, Inc.-- -- -- -$22.8M
-
Which has Higher Returns IDYA or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -765.66% compared to IDEAYA Biosciences, Inc.'s net margin of -93.07%. IDEAYA Biosciences, Inc.'s return on equity of -11.02% beat Sarepta Therapeutics, Inc.'s return on equity of -64.94%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.88.99% -$0.94 $1.1B SRPTSarepta Therapeutics, Inc.7.7% -$3.93 $2.2B -
What do Analysts Say About IDYA or SRPT?
IDEAYA Biosciences, Inc. has a consensus price target of $50.06, signalling upside risk potential of 51.52%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.55 which suggests that it could grow by 32.02%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 SRPTSarepta Therapeutics, Inc.7 13 3 -
Is IDYA or SRPT More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.092, which suggesting that the stock is 90.817% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.424, suggesting its less volatile than the S&P 500 by 57.628%.
-
Which is a Better Dividend Stock IDYA or SRPT?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or SRPT?
IDEAYA Biosciences, Inc. quarterly revenues are $10.9M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $442.9M. IDEAYA Biosciences, Inc.'s net income of -$83.3M is higher than Sarepta Therapeutics, Inc.'s net income of -$412.2M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.41x versus 0.76x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.13.41x -- $10.9M -$83.3M SRPTSarepta Therapeutics, Inc.0.76x 20.50x $442.9M -$412.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 13.86% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 7.76% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 3.24% over the past day.
